Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Its product pipeline include Zilovertamab, ONCT-216, ONCT-808 and ONCT-534. The company was founded by David F. Hale and James B. Breitmeyer in September 1997 and is headquartered in San Diego, CA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A
Frequently Asked Questions
What is Market Cap of Oncternal Therapeutics Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Oncternal Therapeutics Inc market cap is $1.56M.
What is the 52-week high for Oncternal Therapeutics Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Oncternal Therapeutics Inc 52 week high is $0.5266 as of January 10, 2026.
What is the 52-week low for Oncternal Therapeutics Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Oncternal Therapeutics Inc 52 week low is $0.5266 as of January 10, 2026.
What is Oncternal Therapeutics Inc stock price today?
Oncternal Therapeutics Inc stock price today is $0.5266.
What was Oncternal Therapeutics Inc stock price yesterday?
Oncternal Therapeutics Inc stock price yesterday was $0.6939.
What is the 50-day moving average of Oncternal Therapeutics Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Oncternal Therapeutics Inc 50-day moving average is $0.5266.